Certara Inc (CERT)

Certara, Inc. (CERT) is a leading global biosimulation company that aims to advance the health outcomes of patients by using modeling, simulation, and data science. The firm is publicly listed on Nasdaq under the ticker symbol 'CERT.'

Founded in 2008 and headquartered in Princeton, New Jersey, Certara provides its innovative technologies and services to over 1,600 companies, including all top 20 global pharmaceutical companies, hundreds of biotech and specialty pharma firms, regulatory agencies such as the FDA, NIH, and EMA, and academic institutions. The company's tools are used in the development of small molecules, biologics, cell and gene therapies, and consumer health products.

Certara operates under a unique business model. By using a biosimulation approach to drug development, it leverages the use of mathematical models to predict how drugs might behave in different scenarios. This reduces the need for extensive and costly clinical trials and increases the efficiency of the drug discovery process.

At the heart of Certara's offerings is its proprietary flagship software, Simcyp, which is widely recognized for its excellent pharmacokinetic and pharmacodynamic modeling capabilities. Simcyp allows researchers to simulate drug interactions in virtual patient populations and yield data that helps to inform dosing decisions and strategies.

Beyond drug development, Certara also provides strategic regulatory science consulting services to assist clients in obtaining regulatory approval. The firm's regulatory team is comprised of former FDA and EMA reviewers, offering unparalleled insights into global drug regulatory processes.

With over 700 global employees, Certara continues to expand its operations worldwide to better meet the needs of its customers. In December 2020, the company went public through an Initial Public Offering (IPO) on the Nasdaq Global Select Market.

Since its inception, Certara has become a key player in the biosimulation market. Through its unwavering commitment to innovation and application of learning from real-world evidence, this trailblazing firm continues to accelerate the pace of drug discovery and development, bringing safer, more effective medicines to patients sooner.